
MALI Platform
AI Stock Research
Baker Bros. Advisors LP: latest 13F holdings
For the quarter ending 30 September 2026, Baker Bros. Advisors LP reported 80 positions worth $21.0B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $20.0B.
Read the filing at SEC EDGARChecked: the cover page's entry count and total value match the holdings table.
Top 50 positions by value
| # | Issuer | Class | Value | Weight | Shares | vs quarter before |
|---|---|---|---|---|---|---|
| 1 | Incyte Corporation | COM | $3.7B | 17.74% | 30,762,652 | Added 0.0% |
| 2 | BeOne Medicines Ltd. | SPONSORED ADS | $3.2B | 15.36% | 8,832,335 | Added 0.3% |
| 3 | Revolution Medicines, Inc. | COM | $2.2B | 10.38% | 10,637,318 | Cut 7.0% |
| 4 | Kodiak Sciences Inc. | COM | $2.1B | 9.85% | 21,860,941 | Added 9.7% |
| 5 | Madrigal Pharmaceuticals, Inc. | COM | $1.1B | 5.13% | 2,143,131 | Unchanged |
| 6 | Insmed Incorporated | COM PAR $.01 | $1.0B | 4.77% | 8,796,111 | Unchanged |
| 7 | Kymera Therapeutics, Inc. | COM | $967.8M | 4.60% | 8,657,242 | Unchanged |
| 8 | ACADIA Pharmaceuticals Inc. | COM | $864.7M | 4.11% | 42,912,904 | Unchanged |
| 9 | GRAIL, Inc. | COM | $564.5M | 2.68% | 4,028,614 | Unchanged |
| 10 | Summit Therapeutics Inc. | COM | $554.4M | 2.63% | 32,786,348 | Unchanged |
| 11 | Rhythm Pharmaceuticals, Inc. | COM | $533.6M | 2.54% | 5,604,483 | Unchanged |
| 12 | Praxis Precision Medicines, Inc. | COM | $510.6M | 2.43% | 1,753,198 | Unchanged |
| 13 | AbCellera Biologics Inc. | COM | $481.6M | 2.29% | 33,012,139 | Added 0.0% |
| 14 | Alkermes plc | SHS | $405.7M | 1.93% | 10,012,267 | Unchanged |
| 15 | Celcuity Inc. | COM | $383.0M | 1.82% | 4,815,792 | Cut 39.2% |
| 16 | Kiniksa Pharmaceuticals International, plc | ORD SHS CL A | $211.5M | 1.00% | 2,834,643 | Unchanged |
| 17 | IDEAYA Biosciences, Inc. | COM | $192.5M | 0.91% | 5,010,030 | Unchanged |
| 18 | Edgewise Therapeutics, Inc. | COM | $150.3M | 0.71% | 3,701,719 | Unchanged |
| 19 | Replimune Group, Inc. | COM | $146.2M | 0.69% | 11,045,336 | Unchanged |
| 20 | Roivant Sciences Ltd. | SHS | $133.9M | 0.64% | 3,660,352 | Cut 22.4% |
| 21 | Arrowhead Pharmaceuticals, Inc. | COM | $111.9M | 0.53% | 1,709,053 | Cut 14.2% |
| 22 | Nurix Therapeutics, Inc. | COM | $110.5M | 0.52% | 4,658,556 | Unchanged |
| 23 | Immunovant, Inc. | COM | $93.6M | 0.44% | 2,770,377 | Cut 49.0% |
| 24 | Celldex Therapeutics, Inc. | COM | $83.1M | 0.40% | 2,564,984 | Added 116.9% |
| 25 | Denali Therapeutics Inc. | COM | $77.2M | 0.37% | 3,734,336 | Unchanged |
| 26 | Dianthus Therapeutics, Inc. | COM | $75.0M | 0.36% | 852,164 | Unchanged |
| 27 | Celcuity Inc. | Note 2.75% 8/1/2031 | $55.5M | 0.26% | — | New |
| 28 | Rapport Therapeutics, Inc. | COM | $52.0M | 0.25% | 1,547,090 | Unchanged |
| 29 | Monte Rosa Therapeutics, Inc. | COM | $51.8M | 0.25% | 4,345,736 | Unchanged |
| 30 | Relay Therapeutics, Inc. | COM | $51.0M | 0.24% | 2,826,783 | Unchanged |
| 31 | Ionis Pharmaceuticals, Inc. | COM | $45.7M | 0.22% | 1,023,864 | Cut 50.0% |
| 32 | Structure Therapeutics Inc. | SPONSORED ADS | $44.8M | 0.21% | 1,432,529 | Unchanged |
| 33 | Enliven Therapeutics, Inc. | COM | $41.5M | 0.20% | 905,191 | Unchanged |
| 34 | Bicycle Therapeutics plc | SPONSORED ADS | $40.1M | 0.19% | 10,885,357 | Unchanged |
| 35 | Prelude Therapeutics Inc. | COM | $39.6M | 0.19% | 10,123,824 | Unchanged |
| 36 | Mirum Pharmaceuticals, Inc. | COM | $38.1M | 0.18% | 445,975 | Unchanged |
| 37 | Design Therapeutics, Inc. | COM | $37.6M | 0.18% | 2,988,144 | Added 11.6% |
| 38 | Immatics N.V. | SHS | $37.4M | 0.18% | 4,256,682 | Cut 55.2% |
| 39 | Stoke Therapeutics, Inc. | COM | $34.2M | 0.16% | 1,313,999 | Cut 60.6% |
| 40 | Entrada Therapeutics, Inc. | COM | $32.2M | 0.15% | 5,072,730 | Unchanged |
| 41 | Neurogene Inc. | COM | $27.6M | 0.13% | 991,691 | Unchanged |
| 42 | Xencor, Inc. | COM | $27.5M | 0.13% | 1,102,106 | Unchanged |
| 43 | Faeth Therapeutics, Inc. | COM | $23.9M | 0.11% | 803,425 | Cut 37.5% |
| 44 | Absci Corporation | COM | $23.0M | 0.11% | 2,134,803 | Unchanged |
| 45 | Disc Medicine, Inc. | COM | $22.9M | 0.11% | 349,657 | Unchanged |
| 46 | Arcus Biosciences, Inc. | COM | $21.8M | 0.10% | 844,816 | Unchanged |
| 47 | Generate Biomedicines, Inc. | COM SHS | $21.4M | 0.10% | 1,423,602 | Unchanged |
| 48 | Taysha Gene Therapies, Inc. | COM SHS | $19.5M | 0.09% | 4,004,756 | Unchanged |
| 49 | Aktis Oncology, Inc. | COM | $19.4M | 0.09% | 996,351 | Unchanged |
| 50 | Jade Biosciences, Inc. | COM | $17.3M | 0.08% | 1,230,426 | Unchanged |
Showing the largest 50 of 80 positions. Every position is in MALI's SEC Financials & 13F workspace.
New this quarter
- Celcuity Inc. · $55.5M
Sold out
- Crinetics Pharmaceuticals, Inc. · was $88.0M
- Celcuity Inc. · was $69.2M
- Alumis Inc. · was $56.6M
- Viridian Therapeutics, Inc. · was $43.8M
- Sionna Therapeutics, Inc. · was $17.6M
- Verastem, Inc. · was $9.5M
- Sagimet Biosciences Inc. · was $7.4M
- Wave Life Sciences Ltd. · was $4.8M
- Skye Bioscience, Inc. · was $1.1M
- Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1) · was $13.8K
Reading a 13F
A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.
Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.